

Table 10.6a
Immunosuppression Use for Induction, 2000 to 2009
Recipients with Intestine Transplants

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Transplants	82	113	107	116	152	178	175	198	185	180
With Immunosuppression Info	80	112	106	116	149	167	169	194	182	175
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	1.3%	0.0%	0.9%	1.7%	2.7%	1.8%	0.6%	0.5%	0.0%	1.1%
OKT3	5.0%	6.3%	2.8%	1.7%	1.3%	3.6%	14.2%	17.5%	15.4%	21.1%
Thymoglobulin	0.0%	12.5%	31.1%	45.7%	18.8%	15.6%	18.9%	23.7%	33.5%	41.7%
Zenapax	55.0%	24.1%	12.3%	17.2%	12.8%	13.8%	17.2%	9.8%	8.2%	4.0%
Simulect	12.5%	13.4%	13.2%	1.7%	0.7%	3.0%	3.0%	2.1%	0.5%	1.7%
Campath	0.0%	0.0%	1.9%	8.6%	19.5%	22.2%	21.3%	13.4%	18.1%	12.0%
No Induction Drugs Recorded	31.3%	43.8%	39.6%	25.0%	45.6%	45.5%	40.8%	51.0%	40.1%	41.7%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.